Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Inflarx NV - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
IFRX
Nasdaq
8731
https://www.inflarx.de/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Inflarx NV
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
- Mar 21st, 2024 12:45 pm
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
- Mar 21st, 2024 11:00 am
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
- Mar 19th, 2024 11:30 am
Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?
- Mar 6th, 2024 10:27 am
InflaRx Appoints Jan Medina as Head of Investor Relations
- Feb 22nd, 2024 12:30 pm
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
- Jan 25th, 2024 12:30 pm
InflaRx N.V.'s (NASDAQ:IFRX) top owners are individual investors with 55% stake, while 23% is held by institutions
- Jan 25th, 2024 10:30 am
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
- Jan 4th, 2024 12:00 pm
Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing
- Dec 1st, 2023 2:55 pm
After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)
- Nov 28th, 2023 2:35 pm
InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Nov 6th, 2023 2:35 pm
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
- Nov 6th, 2023 12:30 pm
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 1st, 2023 11:30 am
12 Best German Stocks To Buy Now
- Oct 31st, 2023 11:12 pm
Loss-Making InflaRx N.V. (NASDAQ:IFRX) Expected To Breakeven In The Medium-Term
- Oct 10th, 2023 11:18 am
We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth
- Sep 13th, 2023 11:07 am
InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why
- Sep 1st, 2023 6:38 pm
Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More
- Aug 31st, 2023 2:15 pm
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
- Aug 30th, 2023 11:30 am
Retail investors who have a significant stake must be disappointed along with institutions after InflaRx N.V.'s (NASDAQ:IFRX) market cap dropped by US$37m
- Aug 17th, 2023 11:01 am
Scroll